JP2018516883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516883A5 JP2018516883A5 JP2017557899A JP2017557899A JP2018516883A5 JP 2018516883 A5 JP2018516883 A5 JP 2018516883A5 JP 2017557899 A JP2017557899 A JP 2017557899A JP 2017557899 A JP2017557899 A JP 2017557899A JP 2018516883 A5 JP2018516883 A5 JP 2018516883A5
- Authority
- JP
- Japan
- Prior art keywords
- solid form
- form according
- xrpd
- theta
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 claims 19
- 238000000634 powder X-ray diffraction Methods 0.000 claims 14
- 238000001237 Raman spectrum Methods 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 claims 2
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 claims 2
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002329 infrared spectrum Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- IHQSWPOUPYXQNN-XLAORIBOSA-N CC(C)(C)OC(N[C@H](CC1)CC[C@@H]1N[C@H](C1)[C@@H]1c1ccccc1)=O Chemical compound CC(C)(C)OC(N[C@H](CC1)CC[C@@H]1N[C@H](C1)[C@@H]1c1ccccc1)=O IHQSWPOUPYXQNN-XLAORIBOSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021060013A JP2021119136A (ja) | 2015-05-06 | 2021-03-31 | 固体形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166641.9A EP3090998A1 (en) | 2015-05-06 | 2015-05-06 | Solid forms |
| EP15166641.9 | 2015-05-06 | ||
| PCT/EP2016/059726 WO2016177656A1 (en) | 2015-05-06 | 2016-05-02 | Solid forms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021060013A Division JP2021119136A (ja) | 2015-05-06 | 2021-03-31 | 固体形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516883A JP2018516883A (ja) | 2018-06-28 |
| JP2018516883A5 true JP2018516883A5 (enExample) | 2019-06-06 |
| JP7005007B2 JP7005007B2 (ja) | 2022-02-04 |
Family
ID=53039825
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557899A Active JP7005007B2 (ja) | 2015-05-06 | 2016-05-02 | 固体形態 |
| JP2021060013A Pending JP2021119136A (ja) | 2015-05-06 | 2021-03-31 | 固体形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021060013A Pending JP2021119136A (ja) | 2015-05-06 | 2021-03-31 | 固体形態 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10221125B2 (enExample) |
| EP (2) | EP3090998A1 (enExample) |
| JP (2) | JP7005007B2 (enExample) |
| KR (1) | KR102666390B1 (enExample) |
| CN (1) | CN107735394B (enExample) |
| AR (1) | AR104505A1 (enExample) |
| AU (1) | AU2016259054B2 (enExample) |
| BR (1) | BR112017023740B1 (enExample) |
| CA (1) | CA2984203C (enExample) |
| ES (1) | ES2969970T3 (enExample) |
| HU (1) | HUE065558T2 (enExample) |
| IL (1) | IL255194B (enExample) |
| MX (1) | MX378732B (enExample) |
| PL (1) | PL3292100T3 (enExample) |
| WO (1) | WO2016177656A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9487512B2 (en) | 2011-10-20 | 2016-11-08 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| CA3253937A1 (en) | 2016-03-15 | 2025-03-04 | Oryzon Genomics, S.A. | Combinations of Lysine-Specific Demethylase 1 Inhibitors for the Treatment of Hematological Maligna |
| EA201892075A1 (ru) | 2016-03-15 | 2019-04-30 | Оризон Дженомикс, С.А. | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей |
| JP2019512546A (ja) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ |
| US10780081B2 (en) | 2016-06-10 | 2020-09-22 | Oryzon Genomics, S.A. | Method of treating multiple sclerosis employing a LSD1-inhibitor |
| KR102685898B1 (ko) | 2017-08-03 | 2024-07-19 | 오리존 지노믹스 에스.에이. | 행동 변경 치료 방법 |
| CN112040934A (zh) * | 2018-05-04 | 2020-12-04 | 奥莱松基因组股份有限公司 | 稳定的药物制剂 |
| AU2020242302B2 (en) | 2019-03-20 | 2025-10-30 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| CN113631164A (zh) | 2019-03-20 | 2021-11-09 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| AU2020249493B2 (en) * | 2019-03-25 | 2025-08-28 | Oryzon Genomics, S.A. | Combinations of iadademstat for cancer therapy |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| EP4319732A1 (en) | 2021-04-08 | 2024-02-14 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| JP2025516648A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7741086B2 (en) | 2004-12-16 | 2010-06-22 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 |
| DK1704859T3 (da) | 2005-02-18 | 2010-11-22 | Universitaetsklinikum Freiburg | Kontrol af androgen receptor-afhængig genenkspression ved inhibering af amin-oxidase-aktiviteten af lysin-specifik demetylase (LSD1) |
| CN101410367A (zh) | 2005-08-10 | 2009-04-15 | 约翰·霍普金斯大学 | 多胺用在抗寄生虫与抗癌治疗学以及作为赖氨酸-特异性脱甲基酶抑制剂 |
| US20110092601A1 (en) | 2007-04-13 | 2011-04-21 | The Johns Hopkins University | Lysine-specific demethylase inhibitors |
| EP2317992A2 (en) | 2008-07-24 | 2011-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsd1 and a mao inhibitor |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| US9708255B2 (en) | 2009-08-18 | 2017-07-18 | Robert A. Casero | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
| WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| WO2011113005A2 (en) | 2010-03-12 | 2011-09-15 | The Johns Hopkins University | Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) |
| WO2011131697A1 (en) | 2010-04-19 | 2011-10-27 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| EA022459B1 (ru) | 2010-04-20 | 2016-01-29 | Университа' Дельи Студи Ди Рома "Ла Сапиенца" | Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2 |
| DK2598482T3 (en) | 2010-07-29 | 2018-06-14 | Oryzon Genomics Sa | ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| US20140163041A1 (en) | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| JP5813855B2 (ja) | 2011-03-25 | 2015-11-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | Ｌｓｄ１阻害剤としてのシクロプロピルアミン |
| EP2750671A2 (en) | 2011-05-19 | 2014-07-09 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| US9487512B2 (en) | 2011-10-20 | 2016-11-08 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| EP4074695A1 (en) | 2011-10-20 | 2022-10-19 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| AU2016275702A1 (en) | 2015-06-12 | 2017-12-21 | Oryzon Genomics, S.A. | Biomarkers associated with LSD1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017060319A1 (en) | 2015-10-09 | 2017-04-13 | F. Hoffmann-La Roche Ag | Gene expression biomarkers for personalized cancer care to epigenetic modifying agents |
| CA3253937A1 (en) | 2016-03-15 | 2025-03-04 | Oryzon Genomics, S.A. | Combinations of Lysine-Specific Demethylase 1 Inhibitors for the Treatment of Hematological Maligna |
| EA201892075A1 (ru) | 2016-03-15 | 2019-04-30 | Оризон Дженомикс, С.А. | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей |
| JP2019512546A (ja) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ |
| US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
-
2015
- 2015-05-06 EP EP15166641.9A patent/EP3090998A1/en not_active Ceased
-
2016
- 2016-05-02 ES ES16719864T patent/ES2969970T3/es active Active
- 2016-05-02 BR BR112017023740-7A patent/BR112017023740B1/pt active IP Right Grant
- 2016-05-02 CN CN201680025229.8A patent/CN107735394B/zh active Active
- 2016-05-02 WO PCT/EP2016/059726 patent/WO2016177656A1/en not_active Ceased
- 2016-05-02 PL PL16719864.7T patent/PL3292100T3/pl unknown
- 2016-05-02 HU HUE16719864A patent/HUE065558T2/hu unknown
- 2016-05-02 CA CA2984203A patent/CA2984203C/en active Active
- 2016-05-02 EP EP16719864.7A patent/EP3292100B1/en active Active
- 2016-05-02 US US15/571,945 patent/US10221125B2/en active Active
- 2016-05-02 JP JP2017557899A patent/JP7005007B2/ja active Active
- 2016-05-02 AU AU2016259054A patent/AU2016259054B2/en active Active
- 2016-05-02 KR KR1020177035160A patent/KR102666390B1/ko active Active
- 2016-05-02 MX MX2017014035A patent/MX378732B/es unknown
- 2016-05-03 AR ARP160101249A patent/AR104505A1/es unknown
-
2017
- 2017-10-22 IL IL255194A patent/IL255194B/en active IP Right Grant
-
2021
- 2021-03-31 JP JP2021060013A patent/JP2021119136A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516883A5 (enExample) | ||
| JP2021119136A5 (enExample) | ||
| FI3792254T3 (fi) | Kiteisiä metyylitioniniumkloridihydraatteja | |
| TW201612158A (en) | Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof | |
| JP2015500331A5 (enExample) | ||
| JP2019509268A5 (enExample) | ||
| JP2017524733A5 (enExample) | ||
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| JP2016537346A5 (enExample) | ||
| WO2014157612A1 (ja) | （１ｓ，４ｓ，５ｓ）－４－ブロモ－６－オキサビシクロ［３．２．１］オクタン－７－オンの製造方法 | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| RU2010133483A (ru) | Новые кристаллические формы 4-{4-(2-адамантилкарбамоил)-5-третбутилпиразол-1-ил}бензойной кислоты | |
| JP2014530818A5 (enExample) | ||
| JP2012500819A5 (enExample) | ||
| JP2011527687A5 (enExample) | ||
| JP2016510768A5 (enExample) | ||
| JP2018503649A5 (enExample) | ||
| JP2015516425A5 (enExample) | ||
| JP2018509426A5 (enExample) | ||
| WO2024189598A3 (en) | Acylsulfonamide kat6a inhibitors | |
| PH12013500545A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| JP2016510767A5 (enExample) | ||
| JP2018516946A5 (enExample) | ||
| JP2013516475A5 (enExample) |